Steroidal aromatase inhibitor side effects

HCG within the medical field is primarily administered via intramuscular (IM) injections, although it can also be administered subcutaneously, which has also become just as frequent as IM injections. Studies have found that when intramuscular and subcutaneous injections of HCG were compared, the results were almost the exact same for both, indicating almost no difference between the two [4] . The only difference between the two methods of injection is the difference in the rate of release from the injection site and the time required for peak blood plasma levels to be reached (6 hours for IM, and 16 – 20 hours for subcutaneous). The majority of anabolic steroid users will elect to inject HCG subcutaneously.

AB - The choice of treatment for elderly breast cancer patients needs particular care because the presence of physiological functional impairments can modify the drug bioavailability in an unpredictable manner. Hormonal treatment remains one of the choices and, although tamoxifen has proved to be effective in any setting, the use of selective aromatase inhibitors is arousing. Depending on their chemical structure, aromatase inhibitors are either steroidal (such as exemestane and formestane) or non-steroidal (such as letrozole, vorozole and anastrozole). Formestane has been studied in elderly patients with breast cancer and has been found to induce an overall response rate of 51% (95% CI, 35-67%). The drug suppresses estradiol (E2) levels, and changes in other hormones (FSH, LH and SHBG) are observed, but with poor clinical significance, thus confirming its selectivity and potency. Formestane has also been demonstrated to be as effective as tamoxifen. Exemestane and non-steroidal aromatase inhibitors appear to be very promising drugs. Copyright (C) 2000 Elsevier Science Ireland Ltd.

The CHMP decided that Afinitor was shown to slow down disease progression in patients with advanced neuroendocrine tumours of pancreatic origin, advanced renal cell carcinoma and hormone-receptor-positive advanced breast cancer. The CHMP also concluded that the 7 month delay in disease progression for patients with neuroendocrine tumours originating in the lungs or gut was clinically relevant, despite the known side effects of Afinitor. The CHMP concluded that the benefits of Afinitor are greater than its risks and recommended that it be granted marketing authorisation.

Steroidal aromatase inhibitor side effects

steroidal aromatase inhibitor side effects


steroidal aromatase inhibitor side effectssteroidal aromatase inhibitor side effectssteroidal aromatase inhibitor side effectssteroidal aromatase inhibitor side effectssteroidal aromatase inhibitor side effects